PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Design and Evolution: Molecular Sleuthing Reveals Drug Selectivity
June 2015
Families in Gene Neighborhoods
June 2015
Ryanodine Receptor
April 2015
CCR5 and HIV Infection
January 2015
Drug Targets: Bile Acids in Motion
September 2014
Drug Targets: S1R's Ligands and Partners
September 2014
P2Y Receptors and Blood Clotting
September 2014
Bacterial CDI Toxins
June 2014
Glucagon Receptor
April 2014
Viroporins
March 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Design and Discovery: Virtual Drug Screening
January 2014
Cancer Networks: IFI16-mediated p53 Activation
November 2013
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Finding Druggable Targets
October 2013
Drug Discovery: Identifying Dynamic Networks by CONTACT
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
NDM-1 and Antibiotics
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Cytochrome Oxidase
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Regulatory insights
September 2012
Solute Channels
September 2012
Pocket changes
July 2012
Receptor bias
July 2012
Anthrax Stealth Siderophores
June 2012
G Protein-Coupled Receptors
May 2012
Substrate specificity sleuths
April 2012
Reading out regioselectivity
December 2011
Superbugs and Antibiotic Resistance
December 2011
Terminal activation
December 2011
A change to resistance
November 2011
Docking and rolling
October 2011
Breaking down the defenses
September 2011
A2A Adenosine Receptor
May 2011
Cell wall recycler
May 2011
Subtly different
March 2011
CXCR4
January 2011
Subtle shifts
January 2011
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Peptidoglycan binding: Calcium-free killing
June 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Antibiotics and Ribosome Function
March 2010
Safer Alzheimer's drugs?
March 2010
Anthrax evasion tactics
September 2009
GPCR subunits: Separate but not equal
September 2009
Antibiotic target
August 2009
Salicylic Acid Binding Protein 2
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Anthrax stealth molecule
March 2009
Drug targets to aim for
February 2009
High-energy storage system
February 2009
Transporter mechanism in sight
February 2009
Scavenger Decapping Enzyme DcpS
November 2008
Blocking AmtB
September 2008

Research Themes Drug discovery

GPCR subunits: Separate but not equal

PSI-SGKB [doi:10.1038/fa_psisgkb.2009.39]
Featured Article - September 2009
Short description: A functional complementation assay reveals that maximal heterotrimeric G-protein activation is achieved by agonist binding to one subunit of a dopamine D2 receptor dimer.

Cartoon of different D2R dimer activation states, with activation data for these states, from the perspective of agonist-mediated activation of protomer A.

What is the minimal functional unit of a G protein-coupled receptor (GPCR)? Some receptors have been proposed to exist in a 2:1 stoichiometry with heterotrimeric G proteins, although rhodopsin and the β2 adrenergic receptor can activate G proteins in vitro as monomers. In addition, it is not always clear whether agonists bind one or both subunits of a receptor dimer. Reporting in Nature Chemical Biology, Jonathan Javitch and colleagues use a functional complementation assay to study the stoichiometry of human dopamine D2 receptor (D2R) signaling. They find that a D2R dimer binds to a single heterotrimeric G protein and is maximally activated by the binding of an agonist to one receptor protomer.

To study D2R activation, Han et al. fused one D2R (called protomer B) to a novel pertussis-toxin-insensitive Gqi5 chimera that produced calcium-dependent luminescence upon activation. The fusion protein did not signal in response to agonist binding because the very short linker did not allow the G protein to couple to the receptor to which it was fused. However, co-expression of a D2R protomer not fused to a G protein (called protomer A) caused robust agonist-mediated activation. Therefore, agonist-induced D2R signaling is mediated by two receptor protomers and one G protein.

A mutation in protomer A that inhibited agonist binding blocked G-protein-mediated signaling. Surprisingly, this same mutation in protomer B increased G-protein activation compared to the wild-type homodimer. Inverse agonist binding to protomer B also enhanced activation. Thus, the binding of an agonist to one subunit of a dimer is necessary and sufficient for G-protein activation. Intriguingly, agonist binding to protomer B, as well as a constitutively active version of protomer B, both diminished agonist-induced G-protein activation, suggesting that the active conformation of protomer B inhibits signaling and that agonist binding per se is not required for this effect.

Computational modeling and additional mutagenesis studies suggested that the second intracellular loop of both protomers makes contact with the G protein. However, the third intracellular loop of protomer A but not protomer B is required for G-protein activation, which indicates that each protomer in a receptor dimer has a discrete function. Given the apparent asymmetrical role of these protomers and the importance of conformational changes in modulating G-protein activation, it will be interesting to determine the effects of heterodimerization on agonist-stimulated signaling. The complementation assay described in this report will be a useful technique for these future studies.

Related articles

GPCR modeling: any good?

A pocket guide to GPCRs

Evolving a better-expressing GPCR

Emily Chenette

References

  1. Y. Han et al. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation.
    Nature Chem. Biol. (2009). doi:10.1038/nchembio.199

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health